Author and year
Original diagnosis for RT Mean age (yrs.)* F/M Mean RT dose (Gy) Mean latency (yrs.) Mean SRS dose (Gy) Mean tumor volume (cm3 ) WHO grade Mean follow-up (yrs.) Morbidity Tumor progression Jensen et al., 2005 [14 ] 16 3, pituitary tumor 3, astrocytoma 2, tumor NOS 1, oligodendroglioma 1, tinea capitis 1, craniopharyngioma 1, neuroblastoma 1, ALL 1, glioma 1, esthesioneuroblastoma 1, spindle cell tumor 47.5 10/6 55.6 (
) 32.3 margin, 15.9 10.0 — 3.4 1 (6.3%) −1, increased seizure activity 1/19 (5.3%) Kondziolka et al., 2009 [6 ] 19 4, pituitary adenoma 3, medulloblastoma 2, leukemia 2, astrocytoma 1, pilocytic astrocytoma 1, oligodendroglioma 1, craniopharyngioma 1, retinoblastoma 1 rhabdomyosarcoma 1, scalp hemangioma 1, pineal mass 1, experimental 39.5 10/9 42.8 (
) 29.7 margin, 12.9 maximum, 26.2 7.6 5, gr. I 2, gr. II 12, N/A 3.4 1 (5.3%) −1, optic neuropathy 6/24 (25%) Kuhn et al., 2012 [15 ] 12 1, epidermoid carcinoma 2, astrocytoma 1, medulloblastoma 1, tinea capitis 1, lymphoma 1, scalp hemangioma 1, oligodendroglioma 1, neuroblastoma 1, ependymoma 1, pituitary tumor 1, pilocytic astrocytoma 53.1 7/5 52.9 (
) 34.8 margin, 13.6 1.7 2, gr. I 4, gr. II 6, N/A 2.5 2 (16.7%) −1, CN V, VII, and VIII neuropathy −1, left leg weakness and numbness 2/24 (8.3%)